Analysis of 5,844 women revealed that epigenetic age acceleration strongly predicts survival to age 90, with newer-generation clocks showing the most robust associations. Women with slower epigenetic aging had 23-36% higher odds of reaching 90, particularly for advanced clocks like AgeAccelGrim2 and PCGrimAge. However, none of the 15 clocks distinguished between cognitively healthy survivors and those with impairment. This represents the largest systematic comparison of epigenetic aging clocks for predicting exceptional longevity. The findings illuminate a critical gap in current biological age measurement—while these molecular timepieces effectively forecast lifespan, they appear blind to cognitive resilience. This limitation has profound implications for personalized longevity medicine, where maintaining mental acuity alongside physical health defines successful aging. The study suggests we need fundamentally different biomarkers to predict cognitive healthspan, potentially involving brain-specific epigenetic signatures or neuroinflammatory pathways. As this preprint awaits peer review, the results may evolve, but the core finding challenges assumptions about what epigenetic clocks actually measure. The research appears confirmatory rather than paradigm-shifting, validating known clock performance while highlighting their cognitive blind spot.